Update: the meeting highlights are now available.
The committee is being consulted between 14 November – 5 December on the market authorisation for the medicinal product for human use “Saxenda – liraglutide”, granted by Decision C(2015)2133(final) and for “Evenity – romosozumab”, a medicinal product for human use.
Early dialogue and frequent interactions between medicine developers, regulators, health technology assessment bodies (HTAs) and patients can play a key role in delivering robust data needed to enable accelerated access of patients to highly innovative therapies that address unmet medical needs. The chair of EMA’s committee for advanced therapies (CAT), Martina Schussler-Lenz, the chair of EMA’s human medicines committee (CHMP), Harald Enzmann, and the head of EMA’s scientific advice office, Spiros Vamvakas describe these interactions through the example of the recent authorisation of Zynteglo (lentiglobin) in a perspective piece published in Clinical Pharmacology & Therapeutics.
On November 21-22, a couple of month after the first-ever High-Level Meeting on Universal Health Coverage (UHC) is taking place during the UN General Assembly, POLITICO is bringing the Annual Health Care Summit to Amsterdam — a world-renowned life science innovation center and the new home of the European Medicines Agency — for what will be its fourth successful edition. We’ll gather the industry’s top minds together with key policymakers, scientists, business leaders and patient representatives to debate on the policy and cooperative innovations to better public health for the whole of society.
On 11 November 2019, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.V. for a vaccine against Ebola. This vaccine, called Ervebo, had been in development since the Ebola outbreak in West Africa in 2014. It is already used, as part of a specific protocol, to protect people at risk of infection, such as healthcare workers or people who have been exposed to infected persons.
By the European Association of Hospital Pharmacists (EAHP)
The 2019 Medicines Shortages Survey seeks to investigate some of the reasons for medicines shortages in hospitals as well as the impact on patients. In addition, it will identify solutions in place as well as best practices currently applied at local, regional and national level.
The survey targets hospital pharmacists, nurses, physicians, other healthcare professionals working in the hospital environment and patients.